Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 5/2016

01-05-2016 | Original Article

Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with fondaparinux

Authors: Makoto Ikejiri, Hideo Wada, Toshio Yamaguchi, Shinichi Miyazaki, Masahiro Hasegawa, Hiroki Wakabayashi, Kunihiro Asanuma, Akane Sakaguchi, Takeshi Matsumoto, Kohshi Ohishi, Naoki Fujimoto, Norikazu Yamada, Masaaki Ito, Naoyuki Katayama, Akihiro Sudo

Published in: International Journal of Hematology | Issue 5/2016

Login to get access

Abstract

Anti-Xa assays are useful for monitoring the effects of selective anti-Xa drugs, such as fondaparinux, in the prophylaxis of deep vein thrombosis. In the present study, anti-Xa activity was measured using three different assays, Testzym® Heparin S, STA®-Liquid Anti-Xa and HemosIL® Liquid Heparin. Anti-Xa activity in each assay gradually increased from day one after administration to day eight, and still remained on day 15. Although there were significant differences in anti-Xa activity among the three assays, the activity showed significant correlation across assays. There were no significant differences in the anti-Xa activity between patients with and without DVT or between patients with and without massive bleeding on day one before and after administration, day four, day eight and day 15. Anti-Xa activity in each assay was weakly correlated with antithrombin (AT) activity. The AT activity in patients were significantly higher on days four, eight and 15 compared with day one before and after administration, suggesting that AT activity increases following the administration of fondaparinux. The three anti-Xa assay kits tested are useful for monitoring fondaparinux treatment in orthopedic surgery patients.
Literature
1.
van der Hulle T, Dronkers CE, Huisman MV, Klok FA. Current standings in diagnostic management of acute venous thromboembolism: still rough around the edges. Blood Rev. 2016;30:21–6.CrossRefPubMed
2.
Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. VTE Impact Assessment Group in Europe (VITAE): venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemostasis. 2007;98:756–64.
3.
4.
Shindo A, Wada H, Ishikawa H, Ito A, Asahi M, Ii Y, et al. Clinical features and underlying causes of cerebral venous thrombosis in Japanese patients. Int J Hematol. 2014;99:437–40.CrossRefPubMed
5.
Geersing GJ, Zuithoff NP, Kearon C, Anderson DR, Ten Cate-Hoek AJ, Elf JL, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ. 2014;348:g1340.CrossRefPubMedPubMedCentral
6.
Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet. 2011;378:41–8.CrossRefPubMed
7.
Righini M, Le Gal G, Aujesky D, Roy PM, Sanchez O, Verschuren F, Rutschmann O, et al. Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. Lancet. 2008;371:1343–52.CrossRefPubMed
8.
Geerts WH, Heit JA, Clagett P, Pineo GF, Colwell CW, Anderson FA Jr, et al. Prevention of venous thromboembolism. Chest. 2001;119:S132–75.CrossRef
9.
Piovella F, Wang CJ, Lu H, Lee K, Lee LH, Lee WC, et al. AIDA investigators.: deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost. 2005;3:2664–70.CrossRefPubMed
10.
Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:338S–400S.CrossRefPubMed
11.
Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1984 patients. Canadian Collaborative Group. Chest. 1998;114:115S–8S.CrossRefPubMed
12.
Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;132:853–61.CrossRefPubMed
13.
14.
Turpie AG, Gallus AS, Hoek JA, Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001;344:619–25.CrossRefPubMed
15.
Sasaki S, Miyakoshi N, Matsuura H, Saitoh H, Kudoh D, Shimada Y. Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery. J Orthop Sci. 2009;14:491–6.CrossRefPubMed
16.
Yoshida K, Wada H, Hasegawa M, Wakabayashi H, Matsumoto T, Shimokariya Y, et al. Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux. Int J Hematol. 2012;95:160–6.CrossRefPubMed
17.
Hannon MG, Lamont JG. Compartment syndrome due to massive leg hematoma after primary total hip arthroplasty: a previously unreported complication of fondaparinux. J Arthroplasty. 2012;27:1414.e9–11.CrossRef
18.
Aota T, Naitoh K, Wada H, Yamashita Y, Miyamoto N, Hasegawa M, et al. Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban. Int J Hematol. 2014;100:450–6.CrossRefPubMed
19.
Gehrie E, Laposata M. Test of the month: the chromogenic antifactor Xa assay. Am J Hematol. 2012;87:194–6.CrossRefPubMed
20.
Yoshida K, Wada H, Hasegawa M, Wakabayashi H, Ando H, Oshima S, et al. Monitoring for anti-Xa activity for prophylactic administration of fondaparinux in patients with artificial joint replacement. Int J Hematol. 2011;94:355–60.CrossRefPubMed
21.
Schellong SM, Schwarz T, Halbritter K, Beyer J, Siegert G, Oettler W, et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost. 2003;89:228–34.PubMed
22.
Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost. 2014;111:240–8.CrossRefPubMed
23.
Gosselin RC, Francart SJ, Hawes EM, Moll S, Dager WE, Adcock DM. Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level? Ann Pharmacother. 2015;49:777–83.CrossRefPubMed
24.
Hasegawa M, Wada H, Wakabayashi H, Yoshida K, Miyamoto N, Asanuma K, et al. The relationships among hemostatic markers, the withdrawal of fondaparinux due to a reduction in hemoglobin and deep vein thrombosis in Japanese patients undergoing major orthopedic surgery. Clin Chim Acta. 2013;425:109–13.CrossRefPubMed
25.
Ota S, Wada H, Mastuda A, Ogihara Y, Yamada N, Nakamura M, Ito M. Anti-Xa activity in VTE patients treated with fondaparinux. Clin Chim Acta. 2015;442:22–3.CrossRefPubMed
Metadata
Title
Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with fondaparinux
Authors
Makoto Ikejiri
Hideo Wada
Toshio Yamaguchi
Shinichi Miyazaki
Masahiro Hasegawa
Hiroki Wakabayashi
Kunihiro Asanuma
Akane Sakaguchi
Takeshi Matsumoto
Kohshi Ohishi
Naoki Fujimoto
Norikazu Yamada
Masaaki Ito
Naoyuki Katayama
Akihiro Sudo
Publication date
01-05-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-1963-9

Other articles of this Issue 5/2016

International Journal of Hematology 5/2016 Go to the issue

Letter to the Editor

JAK2V617F allele burden in patients with myeloproliferative neoplasms carrying Trisomy 9, and its relationship with clinical phenotypes

Progress in Hematology

Mechanisms of self-renewal in hematopoietic stem cells

Original Article

Comparison of myocardial T1 and T2 values in 3 T with T2* in 1.5 T in patients with iron overload and controls

Original Article

Fibrin-related markers for diagnosing acute-, subclinical-, and pre-venous thromboembolism in patients with major orthopedic surgery

Original Article

Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?

Original Article

Antigen expression on a putative leukemic stem cell population and AML blast
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits